Homocysteine and Stroke Risk
Authors:
- Min ZhaoMZMin Zhao
- Xiaobin WangXWXiaobin Wang
- Mingli HeMHMingli He
- Xianhui QinXQXianhui Qin
- Genfu TangGTGenfu Tang
- Yong HuoYHYong Huo
- Jianping LiJLJianping Li
- Jia FuJFJia Fu
- Xiao HuangXHXiao Huang
- Xiaoshu ChengXCXiaoshu Cheng
- Binyan WangBWBinyan Wang
- Fan Fan HouFHFan Fan Hou
- 1 May 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (5) , 1183-1190
Abstract
Background and Purpose—: Elevated blood homocysteine concentration increases the risk of stroke, especially among hypertensive individuals. Homocysteine is largely affected by the methylenetetrahydrofolate reductase C677T polymorphism and folate status. Among hypertensive patients, we aimed to test the hypothesis that the association between homocysteine and stroke can be modified by the methylenetetrahydrofolate reductase C677T polymorphism and folic acid intervention. Methods—: We analyzed the data of 20 424 hypertensive adults enrolled in the China Stroke Primary Prevention Trial. The participants, first stratified by methylenetetrahydrofolate reductase genotype, were randomly assigned to receive double-blind treatments of 10-mg enalapril and 0.8-mg folic acid or 10-mg enalapril only. The participants were followed up for a median of 4.5 years. Results—: In the control group, baseline log-transformed homocysteine was associated with an increased risk of first stroke among participants with the CC/CT genotype (hazard ratio, 3.1; 1.1–9.2), but not among participants with the TT genotype (hazard ratio, 0.7; 0.2–2.1), indicating a significant gene–homocysteine interaction ( P =0.008). In the folic acid intervention group, homocysteine showed no significant effect on stroke regardless of genotype. Consistently, folic acid intervention significantly reduced stroke risk in participants with CC/CT genotypes and high homocysteine levels (tertile 3; hazard ratio, 0.73; 0.55–0.97). Conclusions—: In Chinese hypertensive patients, the effect of homocysteine on the first stroke was significantly modified by the methylenetetrahydrofolate reductase C677T genotype and folic acid supplementation. Such information may help to more precisely predict stroke risk and develop folic acid interventions tailored to individual genetic background and nutritional status. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00794885.Keywords
This publication has 34 references indexed in Scilit:
- Homocysteine and Coronary Heart Disease: Meta-analysis of MTHFR Case-Control Studies, Avoiding Publication BiasPLOS Medicine, 2012
- Stroke and Stroke Care in ChinaStroke, 2011
- Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trialsThe Lancet, 2011
- Evaluation of MTHFR C677T polymorphism in ischemic and hemorrhagic stroke patients. A case–control study in a Northern Indian populationJournal of the Neurological Sciences, 2011
- B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trialThe Lancet Neurology, 2010
- High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke populationClinical Science, 2009
- Homocysteine and Its Relationship to Stroke Subtypes in a UK Black PopulationStroke, 2008
- Effect of Folic Acid and B Vitamins on Risk of Cardiovascular Events and Total Mortality Among Women at High Risk for Cardiovascular DiseaseJAMA, 2008
- A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertensionEuropean Journal of Human Genetics, 2007
- Homocysteine Lowering and Cardiovascular Events after Acute Myocardial InfarctionNew England Journal of Medicine, 2006